Antibody–drug conjugates

Breaking up is hard to do

A comprehensive genetic screen reveals new cellular trafficking factors and linker-dependent requirements for antibody–drug conjugate (ADC) cytotoxicity. These new insights may guide the design of optimized ADCs.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Mechanisms for drug release from antibody–drug conjugates.

References

  1. 1.

    Mukherjee, A. et al. Hum. Antibodies 27, 53–62 (2019).

  2. 2.

    Coats, S.et al. Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-0272 (2019).

  3. 3.

    Abdollahpour-Alitappeh, M. et al. J. Cell. Physiol. 234, 5628–5642 (2019).

  4. 4.

    Tsui, C. K.et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-019-0342-2 (2019).

  5. 5.

    Hamblett, K. J. et al. Cancer Res. 75, 5329–5340 (2015).

  6. 6.

    Vaites, L. P., Paulo, J. A., Huttlin, E. L. & Harper, J. W. Mol. Cell. Biol. 38, e00392–17 (2017).

  7. 7.

    Gébleux, R., Stringhini, M., Casanova, R., Soltermann, A. & Neri, D. Int. J. Cancer 140, 1670–1679 (2017).

  8. 8.

    Kang, J. C. et al. Nat. Biotechnol. 37, 523–526 (2019).

  9. 9.

    Chalouni, C. & Doll, S. J. Exp. Clin. Cancer Res. 37, 20 (2018).

Download references

Author information

Correspondence to Peter D. Senter.

Ethics declarations

Competing interests

The authors are employees of Seattle Genetics, a company engaged in the field of antibody–drug conjugates.

Rights and permissions

Reprints and Permissions

About this article